The biotech's diversification efforts continue.

The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2026" has been added to ResearchAndMarkets.com's offering.The Co-promotion and Co-marketing Deals in Pharmaceuticals and ...

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

It's been a volatile year for the company, but don't let that scare you away.

Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder ...

Innovative Pharmaceutical Biotech (HK:0399) has released an update. Innovative Pharmaceutical Biotech Limited has entered into a Memorandum of Understanding to potentially acquire a majority stake in ...

Jim Cramer says biotech is now the market's hottest group as buyouts accelerate. Here's what's driving the 2026 rally and how ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper ...

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...